drugset / Trial / NCT04183634

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

NCT04183634

Phase 1 Terminated 31 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to evaluate the adhesion of the test product when compared to the reference product following a single transdermal application.

Timeline

Start
2019-12-03
Primary completion
2020-03-16
Completion
2020-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 18 mg Other

Indications